Figure 3 In vivo activity of Bac7(1-35). Survival curves (A) and viable bacterial counts in liver and spleen homogenates (B) of mice infected with S. enterica after treatment via i.p. with Bac7(1-35) are shown. CBA/Ca mice were infected via i.p. with S. enterica ATCC 14028

(102 CFU/mouse) and Bac7(1-35) at 30 mg/kg was immediately injected via i.p. after bacterial challenge (dotted line). Control mice were given 0.2 ml of PBS (continuous line). Mice were monitored for survival over a 60-day period after infection. *p < 0.05 treated vs untreated mice. Three days after bacterial infection, untreated (squares) and peptide-treated (triangles) mice were killed, and liver (full symbols) and spleen (empty symbols) homogenates were prepared as described in section Methods. Results

are expressed as number Sirolimus nmr of CFU/g organ; bars represent the mean value for each group. In parallel to survival experiments, a group of mice was also analyzed for bacterial load at 3 days post-inoculation, when the infected animals did not show any visible sign of disease. Viable bacterial cells were counted in murine liver and spleen of infected mice and results are reported in Figure 3B. The number of viable bacterial cells in liver and spleen homogenates decreased significantly in the animals treated with the peptide at 30 mg/kg, despite a remarkable variability in each group. In 1/3 of the animals bacteria were undetectable in both the spleen and liver. This result Belnacasan in vivo is in keeping PDK4 with the percentage of mice cured extrapolated by the survival curve (Figure 3A). Given that i.p. injection of as few as 100 salmonellae is lethal for mice, the increased survival times and the eradication of the infection in 1/3 of the peptide-treated animals is a promising result. In addition, the

protective role showed by Bac7(1-35) suggests that the peptide may exert its bactericidal action also in infected cells, since S. typhimurium is an intracellular pathogen and Bac7(1-35) is able to penetrate host cells [14, 15]. In vivo Time-Domain Optical Imaging Following the results with the mouse model of infection, we investigated the in vivo biodistribution of Bac7(1-35) by using a time-domain optical imaging instrument [24] and a derivative of Bac7(1-35), fluorescently labelled with the dye Alexa680, showing an antimicrobial activity comparable to that of the unlabelled peptide (data not shown). The Bac7(1-35)-Alexa680 peptide shows a fast elimination kinetics after i.p. injection, characterized by a specific fluorescence intensity signal in the kidney first and then in the bladder. The compound reaches the kidney and the bladder in respectively 1 and 3 hours after the injection. The in vivo and ex vivo analyses performed after 24 h confirm that the compound has been totally excreted (Figure 4).